Evaluation of Cytomegalovirus (CMV) T-Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation
Cytomegalovirus (CMV) is among the most common infectious complications following allogeneic hematopoietic cell transplantation (allo-HCT). The CMV T-cell immunity panel (CMV-TCIP, Viracor) assesses CMV cell-mediated immunity (CMV-CMI); however, its utility among pediatric allo-HCT recipients remains unknown. A retrospective analysis (January 2020–January 2024) among pediatric (≤ 18 years) allo-HCT recipients with CMV DNAemia and at least one CMV-TCIP test was performed.